Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089258 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00089258: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00089258 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089258, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining different types of biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and sargramostim together with monoclonal antibody 3F8 works in treating patients with neuroblastoma that has not responded to previous treatment.
Interventions
- BIOLOGICAL sargramostim
- DRUG isotretinoin
- BIOLOGICAL monoclonal antibody 3F8
- BIOLOGICAL beta-glucan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089258
The ClinicalTrials.gov registry entry for NCT00089258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which sargramostim is the first listed.
NCT00089258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089258 about?
NCT00089258 is a clinical study titled "Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment". RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal antibody 3F8 by making tum...
What is the current status of trial NCT00089258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2004-07.
What interventions are being tested in trial NCT00089258?
The interventions under investigation include: sargramostim (BIOLOGICAL), isotretinoin (DRUG), monoclonal antibody 3F8 (BIOLOGICAL), beta-glucan (BIOLOGICAL).
Who is sponsoring clinical trial NCT00089258?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.